Matinas BioPharma Investor Relations Material
Latest events
Q2 2024
Matinas BioPharma
Q1 2025
14 May, 2025
Q4 2024
14 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Matinas BioPharma Holdings Inc
Access all reports
Matinas BioPharma Holdings Inc. is a biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology for the oral delivery of small molecules, gene therapies, and vaccines. The company's proprietary LNC platform aims to enhance the absorption and bioavailability of drugs, particularly those used to treat infectious diseases and cardiovascular conditions. The company is headquartered in Bedminster, New Jersey, and its shares are listed on the NYSE.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MTNB
Country
🇺🇸 United States